An observational study in Degenerative Sacroiliitis and Sacroiliac Joint Disruption, sponsored by SI-BONE, Inc.. Completed at 26 sites in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-24.
Sponsored by SI-BONE, Inc. · Observational
The purpose of this study is to evaluate the use of the iFuse Implant System to treat degenerative sacroiliitis (arthritis of the SI joint) and sacroiliac disruption (abnormal separation or tearing of the sacroiliac joint). The iFuse Implant System (iFuse device) is a medical device that is surgically implanted into the sacroiliac (SI) joint during a minimally invasive surgical procedure (one that uses a smaller incision and less damage to the skin and other tissues than standard surgery). The purpose of implanting the device is to stabilize and fuse the SI joint.
42 studies on the registry are indexed under Sacroiliitis; 11 are open to participants now.
This study's enrollment of 194 is above the median of 120 across 13 observational studies indexed under Sacroiliitis.
Browse Sacroiliitis studies →SI-BONE, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects with SI joint pain due to degeneration or disruption of the SI joint
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Age 21-70 at time of screening
2. Patient has lower back pain for >6 months inadequately responsive to conservative care
3. Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following:
i. SI joint disruption:
ii. Degenerative sacroiliitis:
4. Baseline Oswestry Disability Index (ODI) score of at least 30% 5. Baseline SI joint pain score of at least 50 on 0-100 mm visual analog scale 6. Patient has signed study-specific form 7. Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements
Exclusion Criteria:
Other known sacroiliac pathology such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject Success
Composite endpoint of reduction from baseline in VAS back pain score by at least 20 mm, lack of device-related serious adverse events, absence of neurologic worsening and absence of surgical re-intervention.
Time frame: Baseline and 6 months
Change in SI Joint Pain on Visual Analog Scale (VAS) (0-100 mm)
The Visual Analog Scale (VAS) is a 100 mm line on which the subject indicates their level of pain. 0 = no pain. 100 = worst imaginable pain.
Time frame: 24 months
Change in Back Dysfunction
Oswestry Disability Index is a validated patient questionnaire aiming to assess low back pain. The computed scores can be 0% to 100%. Lower scores indicate low disability while high scores indicate high disability. There are 10 questions on the questionnaire. Each has 6 possible answers (0 points - 5 points). If the question is skipped, it's points are subtracted from the denominator. If the raw score is 30 and all 10 questions were answered, the calculation would be 30 / 50 = 60%. If one question was skipped, it would be 30 / 45 = 67%.
Time frame: 24 months
Change in Quality of Life
Change in QOL as measured by Short Form-36 PCS and EQ-5D at post-operative visits
Time frame: Baseline and 24 months
Ambulatory Status
Percentage of population fully ambulatory at 24 months post operatively.
Time frame: 24 months
Work Status
Proportion of non-working subjects who return to work
Time frame: Basline, 24 months
Serious Adverse Events
Occurrence of adverse events meeting the ISO14155:2011 definition of serious occurring during the procedure, at the time of hospital discharge (typically day of or next day after procedure), and at various times in late follow-up.
Time frame: Procedure, discharge, 1,3,6,12,18 and 24 months
| Milestone | Sacroiliac Joint Fusion |
|---|---|
| Started | 194 |
| Treated | 172 |
| Month 1 | 171 |
| Month 3 | 169 |
| Month 6 | 168 |
| Month 12 | 160 |
| Month 18 | 150 |
| Completed | 149 |
| Not completed | 45 |
| Withdrew: Withdrew prior to treatment | 10 |
| Withdrew: Withdrawn from analysis at term site | 12 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Death | 2 |
| Withdrew: Early site termination | 3 |
| Withdrew: Lost to follow-up | 12 |
| Withdrew: Physician decision | 1 |
Composite endpoint of reduction from baseline in VAS back pain score by at least 20 mm, lack of device-related serious adverse events, absence of neurologic worsening and absence of surgical re-intervention.
| percentage of participants | Sacroiliac Joint Fusion |
|---|---|
| Subject Success | 80.5 (74.0 to 85.9) |
The Visual Analog Scale (VAS) is a 100 mm line on which the subject indicates their level of pain. 0 = no pain. 100 = worst imaginable pain.
| units on a scale | Sacroiliac Joint Fusion |
|---|---|
| Change in SI Joint Pain on Visual Analog Scale (VAS) (0-100 mm) | 53.3 ± 27.6 |
Oswestry Disability Index is a validated patient questionnaire aiming to assess low back pain. The computed scores can be 0% to 100%. Lower scores indicate low disability while high scores indicate high disability. There are 10 questions on the questionnaire. Each has 6 possible answers (0 points - 5 points). If the question is skipped, it's points are subtracted from the denominator. If the raw score is 30 and all 10 questions were answered, the calculation would be 30 / 50 = 60%. If one question was skipped, it would be 30 / 45 = 67%.
| units on a scale | Sacroiliac Joint Fusion |
|---|---|
| Change in Back Dysfunction | 24.5 ± 21.1 |
Change in QOL as measured by Short Form-36 PCS and EQ-5D at post-operative visits
| units on a scale | Sacroiliac Joint Fusion |
|---|---|
| SF36 PCS | 8.9 ± 10.6 |
| SF36 MCS | 10.1 ± 11.8 |
| EQ5D TTO | .27 ± .26 |
Percentage of population fully ambulatory at 24 months post operatively.
| percentage of participants | Sacroiliac Joint Fusion |
|---|---|
| Ambulatory Status | 89.2 |
Proportion of non-working subjects who return to work
| percentage of participants | Sacroiliac Joint Fusion |
|---|---|
| Work Status | 25.0 |
Occurrence of adverse events meeting the ISO14155:2011 definition of serious occurring during the procedure, at the time of hospital discharge (typically day of or next day after procedure), and at various times in late follow-up.
| serious adverse event | Sacroiliac Joint Fusion |
|---|---|
| Serious Adverse Events | 100 |
Collected over 1 month, 3 months, 6 months, 12 months, 18 months, 24 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sacroiliac Joint Fusion | — | 67/172 (39%) | 153/172 (89%) |
| Event | Sacroiliac Joint Fusion |
|---|---|
| Degenerative disease - spineMusculoskeletal and connective tissue disorders | 12/172 |
| Contralateral SIJ painMusculoskeletal and connective tissue disorders | 8/172 |
| Back painMusculoskeletal and connective tissue disorders | 5/172 |
| Rotator cuff tearMusculoskeletal and connective tissue disorders | 3/172 |
| Shoulder painMusculoskeletal and connective tissue disorders | 3/172 |
| Revision - SIJ painInjury, poisoning and procedural complications | 3/172 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 3/172 |
| Neck painMusculoskeletal and connective tissue disorders | 2/172 |
| Osteoarthritis of the hipMusculoskeletal and connective tissue disorders | 2/172 |
| Vertebral compression fractureMusculoskeletal and connective tissue disorders | 2/172 |
| Event | Sacroiliac Joint Fusion |
|---|---|
| Back painMusculoskeletal and connective tissue disorders | 34/172 |
| Degenerative disease - spineMusculoskeletal and connective tissue disorders | 28/172 |
| Ipsilateral SIJ painMusculoskeletal and connective tissue disorders | 21/172 |
| Buttock painMusculoskeletal and connective tissue disorders | 19/172 |
| Contralateral SIJ painMusculoskeletal and connective tissue disorders | 18/172 |
| Hip painMusculoskeletal and connective tissue disorders | 9/172 |
| Trochanteric bursitisMusculoskeletal and connective tissue disorders | 9/172 |
| Knee painMusculoskeletal and connective tissue disorders | 7/172 |
| Upper respiratory infectionRespiratory, thoracic and mediastinal disorders | 7/172 |
| UTIRenal and urinary disorders | 5/172 |
| Age, Continuous(Years) | Sacroiliac Joint Fusion |
|---|---|
| Mean | 50.9 (23.5 to 71.6) |
| Sex: Female, Male(Participants) | Sacroiliac Joint Fusion |
|---|---|
| Female | 120 |
| Male | 52 |
| Ethnicity (NIH/OMB)(Participants) | Sacroiliac Joint Fusion |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 165 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Sacroiliac Joint Fusion |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 2 |
| White | 166 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(participants) | Sacroiliac Joint Fusion |
|---|---|
| United States | 172 |
| Baseline SIJ pain(units on a scale) | Sacroiliac Joint Fusion |
|---|---|
| Mean | 79.8 ± 12.8 |
| Baseline ODI(units on a scale) | Sacroiliac Joint Fusion |
|---|---|
| Mean | 55.2 ± 11.5 |
| Baseline EQ-5D(units on a scale) | Sacroiliac Joint Fusion |
|---|---|
| Mean | .43 ± 0.18 |
3 further baseline measures are reported on the registry.
Plan to share: Yes — Data is shared with YODA project.
The record gives a start of Jul 2012, a primary completion of Jan 2015 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SI-BONE, Inc.